Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Amgen's virus-based cancer drug wins European green light

LONDON, Oct 23 (Reuters) - An experimental Amgen  AMGN.O  
drug based on a tumour-killing virus was given a green light by 
European regulators on Friday, paving the way for the novel 
treatment's approval within a couple of months. 
    The decision is a further milestone for a technology that 
has long fascinated scientists but has previously proved 
difficult to harness. 
    The European Medicines Agency said its experts had 
recommended approval of talimogene laherparepvec or "T-Vec" for 
treating melanoma, making it another option among several new 
drugs for fighting for the most deadly form of skin cancer. 
 
 (Reporting by Ben Hirschler; editing by Jason Neely) 
 ((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters 
Messaging: ben.hirschler.thomsonreuters.com@reuters.net)) 
 
Keywords: AMGEN CANCER/EUROPE

Recent news on Oncolytics Biotech

See all news